SEC Form 10-K filed by Neuraxis Inc.
$NRXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth. Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
10-K - Neuraxis, INC (0001933567) (Filer)
SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth. Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere
CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 11, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live we
SC 13D - Neuraxis, INC (0001933567) (Subject)
SC 13G - Neuraxis, INC (0001933567) (Subject)
SC 13G/A - Neuraxis, INC (0001933567) (Subject)
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable